Mersana Therapeutics Inc (NASDAQ: MRSN) has seen a decline in its stock price by -1.44 in relation to its previous close of 4.16. However, the company has experienced a -2.84% decline in its stock price over the last five trading sessions. Seeking Alpha reported 2024-02-28 that Mersana Therapeutics, Inc. (MRSN) Q4 2023 Earnings Call Transcript
Is It Worth Investing in Mersana Therapeutics Inc (NASDAQ: MRSN) Right Now?
The stock has a 36-month beta value of 1.52. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MRSN is 91.80M, and at present, short sellers hold a 9.51% of that float. On April 10, 2024, the average trading volume of MRSN was 2.33M shares.
MRSN’s Market Performance
The stock of Mersana Therapeutics Inc (MRSN) has seen a -2.84% decrease in the past week, with a -29.07% drop in the past month, and a 52.42% gain in the past quarter. The volatility ratio for the week is 8.25%, and the volatility levels for the past 30 days are at 8.32% for MRSN. The simple moving average for the last 20 days is -13.32% for MRSN stock, with a simple moving average of 59.98% for the last 200 days.
Analysts’ Opinion of MRSN
Many brokerage firms have already submitted their reports for MRSN stocks, with JP Morgan repeating the rating for MRSN by listing it as a “Neutral.” The predicted price for MRSN in the upcoming period, according to JP Morgan is $5 based on the research report published on March 19, 2024 of the current year 2024.
Wedbush, on the other hand, stated in their research note that they expect to see MRSN reach a price target of $7, previously predicting the price at $2. The rating they have provided for MRSN stocks is “Outperform” according to the report published on February 29th, 2024.
Guggenheim gave a rating of “Buy” to MRSN, setting the target price at $7 in the report published on February 29th of the current year.
MRSN Trading at -7.13% from the 50-Day Moving Average
After a stumble in the market that brought MRSN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -57.38% of loss for the given period.
Volatility was left at 8.32%, however, over the last 30 days, the volatility rate increased by 8.25%, as shares sank -27.94% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +27.33% upper at present.
During the last 5 trading sessions, MRSN fell by -2.84%, which changed the moving average for the period of 200-days by +26.54% in comparison to the 20-day moving average, which settled at $4.65. In addition, Mersana Therapeutics Inc saw 76.72% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MRSN starting from Protopapas Anna, who sale 29,399 shares at the price of $2.71 back on Jan 16 ’24. After this action, Protopapas Anna now owns 125,153 shares of Mersana Therapeutics Inc, valued at $79,671 using the latest closing price.
Lowinger Timothy B, the SVP, Chief Sci.&Tech. Officer of Mersana Therapeutics Inc, sale 10,409 shares at $2.71 during a trade that took place back on Jan 16 ’24, which means that Lowinger Timothy B is holding 199,329 shares at $28,208 based on the most recent closing price.
Stock Fundamentals for MRSN
Current profitability levels for the company are sitting at:
- -4.67 for the present operating margin
- 0.96 for the gross margin
The net margin for Mersana Therapeutics Inc stands at -4.68. The total capital return value is set at -1.06. Equity return is now at value -266.24, with -61.27 for asset returns.
Based on Mersana Therapeutics Inc (MRSN), the company’s capital structure generated 0.44 points at debt to capital in total, while cash flow to debt ratio is standing at -5.98. The debt to equity ratio resting at 0.78. The interest coverage ratio of the stock is -84.39.
Currently, EBITDA for the company is -169.44 million with net debt to EBITDA at 0.81. When we switch over and look at the enterprise to sales, we see a ratio of 9.6. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.36.
Conclusion
To sum up, Mersana Therapeutics Inc (MRSN) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
